167 related articles for article (PubMed ID: 8250991)
1. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation.
Buttle DJ; Handley CJ; Ilic MZ; Saklatvala J; Murata M; Barrett AJ
Arthritis Rheum; 1993 Dec; 36(12):1709-17. PubMed ID: 8250991
[TBL] [Abstract][Full Text] [Related]
2. Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.
Kozaci LD; Brown CJ; Adcocks C; Galloway A; Hollander AP; Buttle DJ
Mol Pathol; 1998 Oct; 51(5):282-6. PubMed ID: 10193524
[TBL] [Abstract][Full Text] [Related]
3. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures.
Kozaci LD; Buttle DJ; Hollander AP
Arthritis Rheum; 1997 Jan; 40(1):164-74. PubMed ID: 9008612
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation.
Buttle DJ; Saklatvala J
Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):657-61. PubMed ID: 1445226
[TBL] [Abstract][Full Text] [Related]
5. Proteoglycan breakdown from bovine nasal cartilage is increased, and from articular cartilage is decreased, by extracellular ATP.
Brown CJ; Caswell AM; Rahman S; Russell RG; Buttle DJ
Biochim Biophys Acta; 1997 Dec; 1362(2-3):208-20. PubMed ID: 9540852
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.
Bottomley KM; Borkakoti N; Bradshaw D; Brown PA; Broadhurst MJ; Budd JM; Elliott L; Eyers P; Hallam TJ; Handa BK; Hill CH; James M; Lahm HW; Lawton G; Merritt JE; Nixon JS; Röthlisberger U; Whittle A; Johnson WH
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):483-8. PubMed ID: 9163342
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.
Sztrolovics R; White RJ; Roughley PJ; Mort JS
Biochem J; 2002 Mar; 362(Pt 2):465-72. PubMed ID: 11853556
[TBL] [Abstract][Full Text] [Related]
8. The proteoglycan metabolism, morphology and viability of articular cartilage treated with a synthetic matrix metalloproteinase inhibitor.
Steinmeyer J; Daufeldt S; Kalbhen DA
Res Exp Med (Berl); 1997; 197(2):63-79. PubMed ID: 9380952
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage.
Little CB; Hughes CE; Curtis CL; Jones SA; Caterson B; Flannery CR
Arthritis Rheum; 2002 Jan; 46(1):124-9. PubMed ID: 11817583
[TBL] [Abstract][Full Text] [Related]
10. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage.
Loulakis P; Shrikhande A; Davis G; Maniglia CA
Biochem J; 1992 Jun; 284 ( Pt 2)(Pt 2):589-93. PubMed ID: 1599440
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.
Bonassar LJ; Sandy JD; Lark MW; Plaas AH; Frank EH; Grodzinsky AJ
Arch Biochem Biophys; 1997 Aug; 344(2):404-12. PubMed ID: 9264555
[TBL] [Abstract][Full Text] [Related]
12. Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation.
Bryson H; Buttle DJ; Kozaci LD; Johnatty RN; Bunning RA
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):495-501. PubMed ID: 10642507
[TBL] [Abstract][Full Text] [Related]
13. The regulation of MMPs and TIMPs in cartilage turnover.
Cawston T; Billington C; Cleaver C; Elliott S; Hui W; Koshy P; Shingleton B; Rowan A
Ann N Y Acad Sci; 1999 Jun; 878():120-9. PubMed ID: 10415724
[TBL] [Abstract][Full Text] [Related]
14. The G1 domain of aggrecan released from porcine articular cartilage forms stable complexes with hyaluronan/link protein.
Yasumoto T; Bird JL; Sugimoto K; Mason RM; Bayliss MT
Rheumatology (Oxford); 2003 Feb; 42(2):336-42. PubMed ID: 12595632
[TBL] [Abstract][Full Text] [Related]
15. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
[TBL] [Abstract][Full Text] [Related]
16. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.
Sztrolovics R; White RJ; Poole AR; Mort JS; Roughley PJ
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):571-7. PubMed ID: 10215595
[TBL] [Abstract][Full Text] [Related]
17. Bafilomycin A1 inhibits IL-1-stimulated proteoglycan degradation by chondrocytes without affecting stromelysin synthesis.
Yocum SA; Lopresti-Morrow LL; Gabel CA; Milici AJ; Mitchell PG
Arch Biochem Biophys; 1995 Feb; 316(2):827-35. PubMed ID: 7864640
[TBL] [Abstract][Full Text] [Related]
18. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors.
Gendron C; Kashiwagi M; Hughes C; Caterson B; Nagase H
FEBS Lett; 2003 Dec; 555(3):431-6. PubMed ID: 14675751
[TBL] [Abstract][Full Text] [Related]
19. Expression and activity of ADAMTS-5 in synovium.
Vankemmelbeke MN; Holen I; Wilson AG; Ilic MZ; Handley CJ; Kelner GS; Clark M; Liu C; Maki RA; Burnett D; Buttle DJ
Eur J Biochem; 2001 Mar; 268(5):1259-68. PubMed ID: 11231277
[TBL] [Abstract][Full Text] [Related]
20. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures.
Munteanu SE; Ilic MZ; Handley CJ
Arthritis Rheum; 2000 Oct; 43(10):2211-8. PubMed ID: 11037880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
